Rasheda Ali to Join Advisory Board of Brainstorm Cell Th...(scribed in this press release and its ab...),Health

Date:10/16/2007

scribed in this press release and its ability to satisfy all of the closing conditions. The potential risks and uncertainties include, among others, risks associated with BrainStorm Cell Therapeutics Inc.'s limited operating history, history of losses and expectation to incur losses for the foreseeable future; limited cash resources and its need to raise additional capital to execute on its business plan and continue operations; dependence on its license to Ramot's technology and ability to meet its funding and payment obligations included in such license agreement; ability, together with its licensor, to adequately protect the NurOwn(TM) technology; dependence on key executives and on its scientific consultants; ability to identify, negotiate and successfully implement strategic partnering relationships; ability to complete clinical trials successfully and to obtain required regulatory approvals; competition with companies, some of which have greater resources and experience in developing and obtaining regulatory approval for treatments in BrainStorm Cell Therapeutics Inc.'s market; the limited public trading market for BrainStorm Cell Therapeutics Inc.'s stock which may never develop into an active market; and other factors detailed in BrainStorm Cell Therapeutics Inc.'s annual report on Form 10-KSB, quarterly reports on Form 10-QSB, current reports on Form 8-K and other filings with the Securities and Exchange Commission available at http://www.sec.gov/ or by request to the Company. The Company does not undertake any obligation to update forward-looking statements made by us.

Contact: Alyssa Miller

(212) 584-4290; amiller@5wpr.com

'/>"/>

SOURCE BrainStorm Cell Therapeutics Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. WHO lifts HongKong advisory
2. FDA Issues Public Health Advisory on Tysabri, a New Drug for MS
3. Doctors Said – ‘Stop Pressurising NHS Advisory Bod’
4. Mercks Pain Reliever Arcoxia Rejected by US Federal Advisory Panel
5. FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too
6. FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too
7. LifeCycle Pharma Forms Scientific Advisory Board in Solid Organ Transplantation
8. Study casts doubt on keyboard ills
9. Who Board To Discuss Asian Tsunami Related Health Issues
10. Abdominal Crunches Not The Best Option For Wash Board Abs.
11. Computer Keyboards In Hospitals Could Spread Infection To Patients